---
title: "US FDA approves Lantheus' new prostate cancer imaging formulation"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278166659.md"
datetime: "2026-03-06T21:13:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278166659.md)
  - [en](https://longbridge.com/en/news/278166659.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278166659.md)
---

# US FDA approves Lantheus' new prostate cancer imaging formulation

March 6 (Reuters) - The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings’ (LNTH.O) prostate cancer imaging agent, aimed at improving scanning access through increased production capacity.

Shares of the company were up about 3% in extended trading.

The imaging agent, Pylarify, targets prostate-specific membrane antigen (PSMA), a protein that is commonly elevated in prostate cancer cells and used to detect metastatic or recurrent disease in patients.

The new formulation is designed to optimize the manufacturing process and is expected to increase the batch size by about 50%, while also improving margins for the company.

### Related Stocks

- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [LNTH.US](https://longbridge.com/en/quote/LNTH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)

## Related News & Research

- [Lantheus Holdings, Inc. $LNTH Shares Sold by Allspring Global Investments Holdings LLC](https://longbridge.com/en/news/282408197.md)
- [PolyPid To Present New Phase 3 SHIELD II Data On D-PLEX100 At ESCMID 2026](https://longbridge.com/en/news/282665678.md)
- [Should Positive Elsunersen Data And Relutrigine Priority Review Shift the Narrative for Praxis (PRAX) Investors?](https://longbridge.com/en/news/282419526.md)
- [Pancreatic cancer pill shown to nearly double overall survival time, drug company says](https://longbridge.com/en/news/282687539.md)
- [BUZZ-Street View: Analysts upbeat on Revolution pancreatic cancer drug](https://longbridge.com/en/news/282702171.md)